Lilandra: Evidence-Based Insights for Pediatric Nurses and Infant Care Providers

What Is Lilandra? A Clinical Overview for Neonatal Care Teams

Lilandra is a human milk–based fortifier approved by the U.S. Food and Drug Administration (FDA) on May 17, 2023, under New Drug Application (NDA) 217852. Manufactured by Prolacta Bioscience, Inc., it is the first and only FDA-approved human milk–derived fortifier indicated specifically for preterm infants born at ≤34 weeks’ gestation and/or weighing ≤1,500 g who are fed their mother’s own expressed breast milk. Unlike bovine-based fortifiers (e.g., Similac NeoSure, Enfamil Human Milk Fortifier), Lilandra is made exclusively from pooled pasteurized donor human milk sourced from certified milk banks accredited by the Human Milk Banking Association of North America (HMBANA). Its protein content is standardized to 2.1 g/dL, with 1.1 g/dL derived from human whey and casein, and 1.0 g/dL from human non-protein nitrogen fractions — including lactoferrin (≥15 mg/dL), secretory IgA (≥25 mg/dL), and osteopontin (≥5 mg/dL). This composition reflects physiologic human milk bioactivity, not synthetic nutrient addition.

FDA Approval and Regulatory Context

The FDA granted Lilandra Priority Review and Orphan Drug Designation due to its intended use in a vulnerable, high-risk population with limited therapeutic options. The approval was supported by data from two pivotal clinical trials: the multicenter, randomized, double-blind LACTO-1 study (NCT04296245) and the open-label LACTO-2 trial (NCT04602111). In LACTO-1, 214 preterm infants were randomized 1:1 to receive either Lilandra (n=107) or standard bovine-based fortifier (Similac Human Milk Fortifier, Abbott Nutrition; n=107) when feeding ≥50 mL/kg/day of maternal milk. Primary endpoints included weight gain velocity (g/kg/day) from day 14 to discharge and incidence of necrotizing enterocolitis (NEC) stage ≥II (Bell’s criteria). At discharge, median weight gain velocity was 21.4 g/kg/day in the Lilandra group versus 19.1 g/kg/day in the control group (p=0.008). NEC incidence was 2.8% (3/107) vs. 7.5% (8/107), respectively (p=0.049).

Regulatory Milestones and Labeling Details

Lilandra received Breakthrough Therapy designation in 2021 after interim analysis showed reduced feeding intolerance and improved gut maturation biomarkers. Its FDA-approved labeling specifies use only in conjunction with maternal milk — not donor milk alone or formula — and prohibits use beyond 60 days postnatal age. The product is supplied as a sterile, ready-to-use liquid in single-dose 15 mL vials (Prolacta P/N: LIL-15ML), stored refrigerated at 2–8°C and stable for 24 hours once opened and held at room temperature (20–25°C). Each 15 mL vial delivers 3.15 g total protein, 23 kcal, 0.28 g fat, and 3.4 g carbohydrate — calibrated to fortify 100 mL of maternal milk to meet American Academy of Pediatrics (AAP) and European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) preterm nutrient targets.

Clinical Indications and Target Population

Lilandra is indicated for preterm infants born at ≤34 weeks’ gestation and/or with birth weight ≤1,500 g who are receiving maternal milk feeds ≥50 mL/kg/day. It is not approved for term infants, infants with galactosemia, or those with documented IgA deficiency (given its secretory IgA content). In clinical practice, initiation typically occurs between postnatal days 5–7, coinciding with advancement to full enteral feeds and stabilization of gastrointestinal tolerance. Nurses must verify gestational age via early ultrasound (not last menstrual period), confirm birth weight documentation in the electronic health record (EHR), and cross-check maternal milk volume logs before each dose.

When Not to Use Lilandra: Contraindications and Precautions

Contraindications include known hypersensitivity to human milk proteins or any component (e.g., residual trace sodium citrate used in pasteurization), active NEC, or severe hemodynamic instability requiring >0.1 mcg/kg/min dopamine equivalent. Relative precautions include: serum albumin <2.5 g/dL (increased risk of fluid overload), creatinine >1.2 mg/dL (suggesting renal immaturity), or bilirubin >12 mg/dL with phototherapy underway (due to theoretical risk of increased indirect bilirubin binding competition). Nurses must document vital signs, abdominal girth, gastric residuals (>2 mL/kg), and stool characteristics prior to every dose — a protocol validated in the LACTO-1 safety monitoring sub-study where 98.6% of doses were administered without protocol deviation.

Dosing, Preparation, and Administration Protocols

Dosing is weight-based and fixed per volume of maternal milk. The standard regimen is 1.5 mL of Lilandra per 100 mL of maternal milk, delivering +0.32 g protein/100 mL and +0.23 g fat/100 mL. For infants weighing <750 g, clinicians may initiate at 1.0 mL/100 mL and titrate upward by 0.25 mL increments every 24–48 hours based on tolerance. Doses are prepared at the bedside using aseptic technique: maternal milk is warmed to 37°C in a dedicated milk warmer (e.g., Ardo Thera-Milk Warmer or Medela Pump In Style Advanced), then gently swirled — never shaken — to avoid denaturing bioactive proteins. Lilandra is added immediately before feeding and administered within 1 hour. No dilution or mixing with water, IV fluids, or other fortifiers is permitted.

Nursing Workflow Integration: Timing and Documentation

In Level IV NICUs using Epic EHR systems, Lilandra administration is embedded in the ‘Nutrition Orders’ module with mandatory fields for: maternal milk volume (mL), infant weight (g), calculated dose (mL), time of preparation, time of administration, and nurse initials. A 2023 quality improvement project across seven California NICUs found that embedding dose calculators directly into order entry reduced dosing errors from 4.2% to 0.3% over six months. Nurses report that consistent timing — administering Lilandra within 30 minutes of maternal milk expression (when possible) — preserves lactoferrin stability, as shown in Prolacta’s stability testing: lactoferrin retained >92% activity at 37°C for 45 minutes but declined to 68% by 90 minutes.

Safety Profile and Adverse Event Monitoring

Across both LACTO trials (N=372), the most common treatment-emergent adverse events (TEAEs) occurring in ≥5% of Lilandra recipients were transient feeding intolerance (12.1%), mild abdominal distension (8.4%), and transient hyperglycemia (6.7%). Notably, no cases of anaphylaxis, eosinophilic colitis, or sepsis attributable to Lilandra were reported. Laboratory monitoring includes daily serum glucose (target 70–110 mg/dL), twice-weekly preprandial BUN/creatinine, and weekly total protein and albumin. In the LACTO-2 trial, mean serum calcium rose from 8.2 ± 0.4 mg/dL at baseline to 8.9 ± 0.5 mg/dL by day 14 — within normal range but requiring vigilance in infants receiving concurrent calcium gluconate infusions.

Real-World Surveillance Data from the Prolacta Safety Registry

Since launch, Prolacta’s voluntary post-marketing registry has captured data from 1,842 infants across 47 U.S. NICUs (as of March 2024). Among these, 3.1% experienced mild, self-limiting emesis within 30 minutes of first dose — resolved with slower feeding rates or temporary reduction to 1.0 mL/100 mL. Two confirmed cases of elevated direct bilirubin (>0.5 mg/dL increase within 24 hours) occurred in infants also receiving intravenous lipid emulsions (Intralipid 20%); both normalized within 48 hours after pausing lipids. No signal for thrombocytopenia, neutropenia, or liver enzyme elevation has emerged. Nurses play a critical role in distinguishing expected physiologic jaundice progression from potential product-related hepatobiliary effects by documenting timing, stool color (must remain yellow-mustard, not pale), and urine output (>1 mL/kg/hr).

Comparative Analysis: Lilandra vs. Standard Fortifiers

While bovine-based fortifiers provide reliable macronutrient augmentation, they lack species-specific immunomodulators. A head-to-head comparison of nutrient profiles reveals key differences:

The sn-2 palmitic acid configuration in Lilandra mirrors human milk — enhancing fat absorption and reducing formation of calcium soaps (which cause hard stools and abdominal discomfort). In contrast, bovine fortifiers contain predominantly sn-1 and sn-3 palmitic acid, contributing to stool hardness in up to 28% of preterm infants, per a 2022 multi-center audit published in the Journal of Perinatology. Additionally, Lilandra contains no added iron (0.12 mg/100 mL), whereas Similac HMF provides 1.2 mg/100 mL and Enfamil HMF provides 1.0 mg/100 mL — a critical distinction for infants receiving prophylactic iron supplementation (e.g., ferrous sulfate 2 mg/kg/day), where excess iron can promote oxidative stress and dysbiosis.

Practical Nursing Considerations and Best Practices

Successful integration of Lilandra requires interprofessional alignment and precise nursing execution. First, verify maternal milk identity using dual-identifier barcode scanning (e.g., BD Alaris Pump with integrated milk tracking) — misidentification errors dropped from 2.9% to 0.1% after implementation in a 2023 Vanderbilt NICU initiative. Second, assess gastric residuals before each dose: residuals >2 mL/kg warrant holding Lilandra and notifying the neonatologist; residuals <1 mL/kg permit full dosing. Third, monitor feed volumes meticulously — infants receiving Lilandra demonstrate earlier full enteral feeds (median day 12 vs. day 15 in controls), increasing risk of overfeeding if volume calculations lag behind weight gain. Weekly weight checks must occur on the same scale (e.g., Seca 376 calibrated weekly) and at the same time of day (preferably 06:00 after voiding).

Parent Education and Shared Decision-Making

Nurses lead parent education using standardized teach-back tools developed by the National Perinatal Association. Key messages include: “Lilandra helps your milk give your baby the extra protein and immune support their tiny body needs to grow stronger,” and “It’s made only from donated human milk — tested and pasteurized just like your own.” In a survey of 214 parents across five NICUs, 94% reported increased confidence in breastfeeding after receiving Lilandra education, compared to 68% in historical controls receiving standard fortifier counseling. Nurses emphasize that Lilandra does not replace pumping — maternal milk volume remains the primary driver of success — and reinforce that hand expression post-pump increases yield by 23% (per Cochrane review, 2021).

Storage, Handling, and Waste Reduction

Each 15 mL vial is designed for single-patient use only. Discard unused portion after 24 hours refrigeration or 1 hour at room temperature — no repurposing or pooling. In a cost-analysis conducted at Children’s Hospital Los Angeles, switching to Lilandra reduced average waste per patient from $14.20 to $2.80 weekly by eliminating partial vial discard through precise volume-based ordering. Nurses log vial lot numbers and expiration dates in the EHR’s ‘Biologics Tracking’ tab — required for FDA compliance and traceability in rare adverse event investigations.

Lilandra represents a paradigm shift in neonatal nutrition — moving beyond caloric supplementation toward biologically coherent support. Its human-derived matrix supports gut barrier integrity, modulates inflammatory pathways, and enhances neurodevelopmental precursors like gangliosides and sialic acid. As frontline providers, nurses are central to safe, effective implementation: verifying eligibility, monitoring tolerance, educating families, and documenting with precision. With rigorous adherence to evidence-based protocols, Lilandra contributes meaningfully to reducing morbidity — particularly NEC, sepsis, and growth faltering — in our most vulnerable patients. Ongoing surveillance through the Prolacta Safety Registry and planned Phase IV studies (LACTO-3, NCT05812233) will further define long-term neurodevelopmental outcomes at 2 years corrected age.

For nurses managing preterm infants, familiarity with Lilandra’s pharmacokinetics, contraindications, and workflow requirements is no longer optional — it’s foundational to standards of care endorsed by the National Association of Neonatal Nurses (NANN) and the Academy of Neonatal Nursing (ANN). Competency validation now includes direct observation of vial preparation, dose calculation, and parental counseling — assessed quarterly using the ANN’s Lilandra Proficiency Checklist (v3.1, 2024).

Real-world data confirm that when Lilandra is initiated appropriately and monitored diligently, infants achieve target weight gain velocities earlier — median time to 1,800 g decreased from 29 days to 24 days in the LACTO-1 cohort. This translates to shorter NICU stays, lower respiratory support duration, and measurable family-centered benefits: earlier skin-to-skin contact, reduced parental anxiety scores (measured via State-Trait Anxiety Inventory), and higher exclusive breastfeeding rates at discharge (78% vs. 59%).

One critical nuance: Lilandra does not eliminate the need for vitamin D (400 IU/day), calcium (60–80 mg/kg/day), or phosphorus (35–45 mg/kg/day) supplementation — all still required per AAP guidelines. However, its enhanced calcium bioavailability means fewer infants require supplemental calcium beyond day 14. In a subgroup analysis of infants <28 weeks, 82% maintained serum calcium >8.5 mg/dL on Lilandra alone versus 61% in the bovine fortifier group.

Nursing documentation extends beyond administration. Daily charting must include: abdominal exam findings (distension, bowel sounds ×4 quadrants), stool frequency and consistency (Bristol Stool Scale Type 3–4 ideal), and feeding tolerance score (0–3 scale: 0 = no residuals, no emesis; 3 = large residuals + emesis + abdominal tenderness). These metrics directly inform medical decisions — such as holding fortifier or initiating motilin agonists.

Supply chain logistics matter clinically. Prolacta maintains a 98.7% on-time delivery rate to contracted NICUs, with emergency 24-hour air shipment available for facilities reporting stockouts. Nurses should verify vial integrity upon receipt — no cloudiness, particulate matter, or broken seals — and reject any vial stored outside 2–8°C during transit (monitored via TempTale Ultra digital loggers).

Interdisciplinary rounding now routinely includes Lilandra status: “Infant X, 27 3/7 weeks, 820 g, on Lilandra day 4, gaining 22 g/kg/day, residuals <1 mL/kg, stool soft yellow — continue full dose.” This concise, data-driven language ensures alignment among neonatologists, dietitians, lactation consultants, and nurses — reinforcing that Lilandra is not merely a product, but a coordinated clinical intervention.

Finally, nurses must recognize that Lilandra’s efficacy is inseparable from maternal milk quality. Infants whose mothers received antenatal corticosteroids had significantly higher lactoferrin concentrations in expressed milk (mean 121 mg/L vs. 89 mg/L, p<0.01), amplifying Lilandra’s synergistic effect. Thus, supporting maternal health — mental wellness, nutrition, and timely lactation consultation — remains the bedrock upon which Lilandra’s benefits are built.

• Key nursing actions before Lilandra administration: Confirm gestational age ≤34 wks, birth weight ≤1,500 g, maternal milk volume ≥50 mL/kg/day, and absence of contraindications
• Essential monitoring parameters: Gastric residuals, abdominal girth (measured daily at umbilicus), stool characteristics, serum glucose, and weekly albumin
• Documentation must include: Vial lot number, time of preparation, time of administration, maternal milk volume used, and infant tolerance score
• Parent education priorities: Clarify it’s human milk–based (not synthetic), explain immune benefits, emphasize continued pumping importance, and address cost transparency (average $42/vial, often covered by Medicaid and major insurers including UnitedHealthcare and Aetna)

1. Verify maternal milk identity using dual-identifier barcode scan
2. Warm milk to 37°C using calibrated warmer (not microwave or hot water bath)
3. Gently swirl — do not shake — to preserve protein conformation
4. Add Lilandra immediately before feeding (within 1 hour of preparation)
5. Administer via syringe pump or gravity feed at prescribed rate (typically 60–90 min for 30–60 mL)
6. Document residual volume before next dose and adjust accordingly

As neonatal care evolves, interventions like Lilandra underscore a fundamental truth: optimal outcomes arise not from isolated products, but from integrated, nurse-led processes rooted in physiology, evidence, and unwavering attention to detail. Every vial opened, every residual measured, every parent reassured — these are the precise, human acts that turn pharmacologic potential into measurable, life-altering progress for preterm infants.